A non-inferiority, phase III trial of gemcitabine plus capecitabine <i>versus</i> gemcitabine plus carboplatin as first-line therapy and tumor-infiltrating lymphocytes as a prognostic biomarker in patients with advanced triple-negative breast cancer

Authors

Weipeng Zhao
Shufen Li (ORCID: https://orcid.org/0000-0003-4917-9278)
Zhongsheng Tong (ORCID: https://orcid.org/0000-0001-8060-5699)
Yehui Shi
Chunfang Hao
Pin Zhang (ORCID: https://orcid.org/0000-0002-7141-9541)
Yongsheng Jia (ORCID: https://orcid.org/0009-0007-9115-3676)
Chen Wang (ORCID: https://orcid.org/0009-0003-2924-3399)
Xu Wang (ORCID: https://orcid.org/0000-0002-2092-4054)
Xiaodong Liu (ORCID: https://orcid.org/0009-0006-7164-426X)

Institutions

Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
Tianjin Medical University Cancer Institute and Hospital (CN)

Publication Details

Journal: Therapeutic Advances in Medical Oncology
Published: 2024-10-01
DOI: https://doi.org/10.1177/17588359241240304
Citations: 2
Primary Topic: PARP inhibition in cancer therapy
Type: article
Field-Weighted Citation Impact: 0.57

Funders

National Natural Science Foundation of China
Tianjin Medical University

Controls

|||

ALL TIME

JAN

FEB

MAR

APR

MAY

JUN

JUL

AUG

SEP

OCT

article

A non-inferiority, phase III trial of gemcitabine plus capecitabine versus gemcitabine plus carboplatin as first-line therapy and tumor-infiltrating lymphocytes as a prognostic biomarker in patients with advanced triple-negative breast cancer

Weipeng Zhao, Shufen Li, Zhongsheng Tong, Yehui Shi et al.

Oct 1, 2024

2 citations

Therapeutic Advances in Medical Oncology

PARP inhibition in cancer therapy

0.57

article

A non-inferiority, phase III trial of gemcitabine plus capecitabine versus gemcitabine plus carboplatin as first-line therapy and tumor-infiltrating lymphocytes as a prognostic biomarker in patients with advanced triple-negative breast cancer

Weipeng Zhao, Shufen Li, Zhongsheng Tong, Yehui Shi, Chunfang Hao, Pin Zhang, Yongsheng Jia, Chen Wang, Xu Wang, Xiaodong Liu

October 1, 2024article en

2 citations

Abstract

No abstract available for this paper.

Therapeutic Advances in Medical OncologyVol. 16

Chinese Academy of Medical Sciences & Peking Union Medical College (CN), Tianjin Medical University Cancer Institute and Hospital (CN)

National Natural Science Foundation of China, Tianjin Medical University

Good health and well-being

Openalex Percentile: Top 26%

PARP inhibition in cancer therapy

0.57

DOI Open Access PDF OpenAlex

AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.